Boston Biomedica appoints investment company:
This article was originally published in Clinica
Boston Biomedica (West Bridgewater, Massachusetts) has hired the investment banking group William Blair & Co to evaluate opportunities to increase shareholder value and raise capital for growth.
You may also be interested in...
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.